Status:
COMPLETED
Correlation Between RISANKIZUMAB's Trough Levels, Clinical and Biological Remission in Moderate to Severe Crohn's Disease: a Retrospective Multicentric Study
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Inflammatory Bowel Diseases
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this observational study is to determine if, as with other therapeutics such as anti-TNF, trough levels of Risankizumab are correlated with clinical and biological remission in patients wi...
Detailed Description
The treatment of chronic inflammatory bowel disease has undergone a number of therapeutic revolutions in recent years, with the emergence of new biotherapies. These include RISANKIZUMAB, an anti-IL23 ...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Patients with moderate to severe Crohn's disease
- Failure of at least one immunosuppressant and one anti-TNF alpha agent
- Patients on Risankizumab
- No opposition to study participation
Exclusion
- Age \< 18 years
- UC
- Unclassified colitis
- Risankizumab prescribed to prevent post-operative relapse
- Any contraindication to Risankizumab
- Refusal to participate in study
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 30 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06589895
Start Date
June 1 2021
End Date
May 30 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire de Nîmes
Nîmes, Gard, France, 30029